Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(5):704–710. doi: 10.1038/bjc.1996.425

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.

Y Kano 1, M Akutsu 1, S Tsunoda 1, J Ando 1, J Matsui 1, K Suzuki 1, T Ikeda 1, Y Inoue 1, K Adachi 1
PMCID: PMC2074704  PMID: 8795571

Abstract

We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PA1 and WiDr. The cells were exposed simultaneously to paclitaxel and to 5-fluorouracil for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days respectively. In another experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was determined by MTT reduction assay. The effects of drug combinations at IC80 were analysed by the isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent. Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549, MCF7 and WiDr cell lines, whereas it showed additive effects in PA1 cells. Sequential exposure to paclitaxel followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PA1 cells. Whereas it showed additive effects in WiDr cells. These findings suggest that maximum cytotoxic effects can be obtained when paclitaxel precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PA1 and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration. These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.

Full text

PDF
704

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arbuck S. G. Paclitaxel: what schedule? What dose? J Clin Oncol. 1994 Feb;12(2):233–236. doi: 10.1200/JCO.1994.12.2.233. [DOI] [PubMed] [Google Scholar]
  2. Aschele C., Sobrero A., Faderan M. A., Bertino J. R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992 Apr 1;52(7):1855–1864. [PubMed] [Google Scholar]
  3. Donehower R. C., Rowinsky E. K. An overview of experience with TAXOL (paclitaxel) in the U.S.A. Cancer Treat Rev. 1993;19 (Suppl 100):63–78. doi: 10.1016/0305-7372(93)90049-w. [DOI] [PubMed] [Google Scholar]
  4. Donehower R. C., Rowinsky E. K., Grochow L. B., Longnecker S. M., Ettinger D. S. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987 Dec;71(12):1171–1177. [PubMed] [Google Scholar]
  5. Grem J. L., Tutsch K. D., Simon K. J., Alberti D. B., Willson J. K., Tormey D. C., Swaminathan S., Trump D. L. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep. 1987 Dec;71(12):1179–1184. [PubMed] [Google Scholar]
  6. Gupta R. S. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep. 1985 May;69(5):515–521. [PubMed] [Google Scholar]
  7. Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
  8. Kano Y., Ohnuma T., Okano T., Holland J. F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 1988 Jan 15;48(2):351–356. [PubMed] [Google Scholar]
  9. Kano Y., Sakamoto S., Kasahara T., Akutsu M., Inoue Y., Miura Y. Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture. Leuk Res. 1991;15(11):1059–1066. doi: 10.1016/0145-2126(91)90112-7. [DOI] [PubMed] [Google Scholar]
  10. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992 Feb 20;50(4):604–610. doi: 10.1002/ijc.2910500420. [DOI] [PubMed] [Google Scholar]
  11. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem. 1981 Oct 25;256(20):10435–10441. [PubMed] [Google Scholar]
  12. Lai G. M., Chen Y. N., Mickley L. A., Fojo A. T., Bates S. E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991 Nov 11;49(5):696–703. doi: 10.1002/ijc.2910490512. [DOI] [PubMed] [Google Scholar]
  13. Lopes N. M., Adams E. G., Pitts T. W., Bhuyan B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993;32(3):235–242. doi: 10.1007/BF00685842. [DOI] [PubMed] [Google Scholar]
  14. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  16. Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. doi: 10.1093/jnci/85.5.384. [DOI] [PubMed] [Google Scholar]
  17. Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988 Jul 15;48(14):4093–4100. [PubMed] [Google Scholar]
  18. Rowinsky E. K., Gilbert M. R., McGuire W. P., Noe D. A., Grochow L. B., Forastiere A. A., Ettinger D. S., Lubejko B. G., Clark B., Sartorius S. E. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991 Sep;9(9):1692–1703. doi: 10.1200/JCO.1991.9.9.1692. [DOI] [PubMed] [Google Scholar]
  19. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  20. Schiff P. B., Horwitz S. B. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry. 1981 May 26;20(11):3247–3252. doi: 10.1021/bi00514a041. [DOI] [PubMed] [Google Scholar]
  21. Wani M. C., Taylor H. L., Wall M. E., Coggon P., McPhail A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325–2327. doi: 10.1021/ja00738a045. [DOI] [PubMed] [Google Scholar]
  22. Wiernik P. H., Schwartz E. L., Einzig A., Strauman J. J., Lipton R. B., Dutcher J. P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. doi: 10.1200/JCO.1987.5.8.1232. [DOI] [PubMed] [Google Scholar]
  23. Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994 Aug;12(8):1621–1629. doi: 10.1200/JCO.1994.12.8.1621. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES